Pulmonary/Respiratory Diseases | Phase II Developments | UNITED STATES

Bellerophon Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Bellerophon Signs Agreement with the FDA on its Planned Pivotal Phase 3 Study

Lead Product(s): Nitric Oxide

Therapeutic Area: Pulmonary/Respiratory Diseases

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 10, 2020

Details:

The Company, has finalized the key elements of its planned pivotal Phase 3 study, including the use of moderate to vigorous physical activity (MVPA) as the primary endpoint for approval.

Pliant Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Pliant Therapeutics Raises $100 Million in Series C Financing to Advance Therapies for Fibrotic Diseases

Lead Product(s): PLN-74809

Therapeutic Area: Pulmonary/Respiratory Diseases

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Novartis

Deal Size: $100.0 million Upfront Cash: Undisclosed

Deal Type: Series C Financing March 03, 2020

Details:

Pliant plans to use the proceeds from the financing to support the continued clinical development of PLN-74809 in idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC).

Genentech Inc

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

FDA Grants Breakthrough Therapy Designation for Genentech’s Esbriet pirfenidone

Lead Product(s): Pirfenidone

Therapeutic Area: Pulmonary/Respiratory Diseases

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 03, 2020

Details:

The designation is based on results from a Phase II trial, which suggested Esbriet slowed disease progression in patients with uILD at 24 weeks.

Respivant Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Respivant Sciences Supports International Rare Disease Day Through Awareness Activities

Lead Product(s): Cromolyn Sodium

Therapeutic Area: Pulmonary/Respiratory Diseases

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 28, 2020

Details:

Respivant also announces 50% enrollment milestone achieved in SCENIC, a Phase 2b Trial of RVT-1601 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF).

Promedior

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Promedior Announces Completion of Acquisition by Roche

Lead Product(s): PRM-151

Therapeutic Area: Pulmonary/Respiratory Diseases

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Roche

Deal Size: $1,390.0 million Upfront Cash: $390.0 million

Deal Type: Acquisition February 13, 2020

Details:

With this acquisition, Roche obtained full rights to Promedior's entire portfolio of molecules for serious fibrotic diseases, notably PRM-151.

PhaseBio Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

PhaseBio Announces Case Study Highlighting PB1046 Hemodynamic Data

Lead Product(s): Vasomera

Therapeutic Area: Pulmonary/Respiratory Diseases

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 04, 2020

Details:

Data continue to support potential of once-weekly VIP analogue for adults with pulmonary arterial hypertension.

Insmed Inc

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Insmed Announces Positive Top-Line Results from Phase 2 WILLOW Study

Lead Product(s): INS1007

Therapeutic Area: Pulmonary/Respiratory Diseases

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 03, 2020

Details:

Study Achieves Primary Endpoint with Statistically Significant Improvement in Time to First Exacerbation for Both Dosage Strengths of INS1007 Versus Placebo.